Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Koi CBD is a U.S.-based private cannabinoid wellness company founded in 2015 that markets hemp-derived consumer products including CBD, delta-8 THC, delta-9 THC, THCA, CBG, kratom, mushroom, and related wellness offerings. The company operates primarily as a commercial branded products business rather than a drug-development biotech, selling tinctures, gummies, vapes, topicals, and other ingestible products through direct-to-consumer and wholesale channels. Koi emphasizes third-party lab testing, U.S.-grown hemp sourcing, and broad distribution as part of its brand positioning. Its business is focused on alternative wellness and recreational/functional cannabinoid categories, not regulated prescription therapeutics or a clinical pharmaceutical pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Koi CBD.